Patent intelligence · US
US 12370194
Metalloenzyme inhibitor compounds
Metalloenzyme inhibitor compounds
Patent details — US 12370194
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 29, 2025
- Expiration
- Jul 24, 2045
- Applicant
- Eikonizo Therapeutics, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K31/506
Quick answer
US 12370194 (Metalloenzyme inhibitor compounds) is held by Eikonizo Therapeutics, Inc.. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Eikonizo Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/506
More from Eikonizo Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12370194?
US 12370194 (Metalloenzyme inhibitor compounds) is held by Eikonizo Therapeutics, Inc.. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12370194?
Eikonizo Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12370194 expire?
Our index shows an expiration date of Jul 24, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.